Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician

Tobler, Diana L.; Pruzansky, Alix J.; Naderi, Sahar; Ambrosy, Andrew P.; Slade, Justin J.

doi:10.1007/s11883-022-01032-8

Cited by 60 publications

(58 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Acute cardiovascular complications of COVID-19 infection include myocarditis, pericarditis, acute coronary syndrome, heart failure, pulmonary hypertension, right ventricular dysfunction, and arrhythmia [9].…”

Section: Negative Effectsmentioning

confidence: 99%

Long Term Effects Post-COVID-19

2022

DHR Proceedings

View full text Add to dashboard Cite

Section: Negative Effectsmentioning

confidence: 99%

Long Term Effects Post-COVID-19

2022

DHR Proceedings

View full text Add to dashboard Cite

“…In the acute phase of severe COVID-19, the main cardiovascular complications are myocarditis, myocardial injury and infarction, heart failure, acute coronary syndrome, pulmonary hypertension, right ventricular dysfunction, and arrhythmia [ 7 , 8 ]. Of note, increasing evidence highlighted the incidence of cardiovascular complications as a long-term consequence of COVID-19 [ 9 ]. On the other hand, in severe disease the cardiovascular manifestations are often a product of the worsening of previously existing conditions.…”

Section: Introductionmentioning

confidence: 99%

In Vitro Evidence of Statins’ Protective Role against COVID-19 Hallmarks

et al. 2022

View full text Add to dashboard Cite

Despite the progressions in COVID-19 understanding, the optimization of patient-specific therapies remains a challenge. Statins, the most widely prescribed lipid-lowering drugs, received considerable attention due to their pleiotropic effects, encompassing lipid metabolism control and immunomodulatory and anti-thrombotic effects. In COVID-19 patients, statins improve clinical outcomes, reducing Intensive Care Unit admission, the onset of ARDS, and in-hospital death. However, the safety of statins in COVID-19 patients has been debated, mainly for statins’ ability to induce the expression of the ACE2 receptor, the main entry route of SARS-CoV-2. Unfortunately, the dynamic of statins’ mechanism in COVID-19 disease and prevention remains elusive. Using different in vitro models expressing different levels of ACE2 receptor, we investigated the role of lipophilic and hydrophilic statins on ACE2 receptor expression and subcellular localization. We demonstrated that the statin-mediated increase of ACE2 receptor expression does not necessarily coincide with its localization in lipid rafts domains, particularly after treatments with the lipophilic atorvastatin that disrupt lipid rafts’ integrity. Through a proteomic array, we analyzed the cytokine patterns demonstrating that statins inhibit the release of cytokines and factors involved in mild to severe COVID-19 cases. The results obtained provide additional information to dissect the mechanism underlying the protective effects of statin use in COVID-19.

show abstract

“…The cardiovascular (CV) system can often be affected during SARS-CoV-2 infection and several acute manifestations, such as myocardial infarction, pericarditis, myocarditis and arrhythmias have been described [ 1 ]. However, also long-term post-COVID-19 CV manifestations have been described [ 2 , 3 ] and an initial myocardial injury has been associated with increased mortality [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Electrocardiographic Abnormalities in Hospitalized Patients with COVID-19 and the Associations with Clinical Outcome

Carubbi

Alunno

Carducci

et al. 2022

JCM

View full text Add to dashboard Cite

The cardiovascular (CV) system can often be affected during SARS-CoV-2 infection and several acute manifestations, such as myocardial infarction, pericarditis, myocarditis and arrhythmias have been described. We provide a retrospective overview of electrocardiographic (ECG) features and their relationship with clinical outcomes in a cohort of patients admitted to our COVID-19 Unit between November 2020 and May 2021. Resting standard 12-lead ECGs were performed in all patients at admission and in those recovering from SARS-CoV-2 infection also at discharge. Clinical and serological records alongside ECG measurements were retrospectively evaluated and statistical analysis was performed to identify relationships between variables. A total of 123 patients (44% females) with a mean age of 73.9 years were enrolled. Ninety-five (77%) patients recovered from SARS-CoV-2 infection and were discharged while 28 (23%) died in hospital. Almost 90% of patients displayed at least one CV risk factor and 41 (33%) patients had at least one previous CV event. We observed that heart rate, corrected QT interval dispersion (QTcd) and inverted T waves are independently associated with in-hospital death and inverted T waves show the strongest association. This association remained significant even after correcting for the number of CV risk factors at baseline and for the type of CV risk factor at baseline. Our study demonstrated that some ECG abnormalities at admission are independently associated with in-hospital death regardless of pre-existing CV risk factors. These findings may be of particular relevance in clinical settings with limited access to advanced techniques, such as cardiac magnetic resonance and could help improve the outcomes of patients with cardiac involvement related to SARS-CoV-2 infection.

show abstract

Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician

Cited by 60 publications

References 58 publications

Long Term Effects Post-COVID-19

Long Term Effects Post-COVID-19

In Vitro Evidence of Statins’ Protective Role against COVID-19 Hallmarks

Electrocardiographic Abnormalities in Hospitalized Patients with COVID-19 and the Associations with Clinical Outcome

Contact Info

Product

Resources

About